Related Experiment Video
Updated: Nov 30, 2025
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report
Jingxian Chen1, Chien-Shan Cheng2,3, Jie Chen4
1Department of Traditional Chinese Medicine, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, China.
Abstract:
The aim of the present study was to report a rare case of head and neck adenocarcinoma with an unknown primary site in a 59-year-old man. After disease progression followed by multiple cycles of chemotherapy and radiotherapy, genetic screening using next-generation sequencing identified vascular endothelial growth factor A amplification and the TP53 R209Kfs mutation. Treatment with the multi-targeted protein kinase inhibitor sorafenib controlled the patient's symptoms and improved his quality of life.
Insights
This study reports a rare head and neck cancer case. Genetic screening revealed specific mutations, and targeted therapy with sorafenib improved patient outcomes.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Head and neck cancers represent a diverse group of malignancies.
- Adenocarcinoma of unknown primary site presents diagnostic and therapeutic challenges.
- Standard treatments like chemotherapy and radiotherapy may be insufficient for advanced disease.
Observation:
- A 59-year-old male presented with advanced head and neck adenocarcinoma of unknown primary.
- The patient experienced disease progression despite multiple cycles of chemotherapy and radiotherapy.
- Next-generation sequencing was employed for comprehensive genetic profiling.
Findings:
- Genetic analysis identified vascular endothelial growth factor A (VEGF-A) amplification.
- A significant TP53 R209Kfs mutation was detected in the tumor.
- These molecular alterations guided subsequent treatment decisions.
Implications:
- Targeted therapy with sorafenib, a multi-targeted protein kinase inhibitor, was initiated.
- Sorafenib effectively controlled the patient's symptoms, improving quality of life.
- This case highlights the potential of precision medicine in managing rare cancers with specific genetic profiles.
More Related Videos
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019